US 11,655,303 B2
Anti-CD39 antibody compositions and methods
Scott Chappel, Milton, MA (US); Andrew Lake, Westwood, MA (US); Michael Warren, North Chelmsford, MA (US); Austin Dulak, Reading, MA (US); Erik Devereaux, Hanover, MA (US); Pamela M. Holland, Belmont, MA (US); Tauqeer Zaidi, Sharon, MA (US); Matthew Rausch, Cambridge, MA (US); Bianka Prinz, Lebanon, NH (US); Nels P. Nielson, Lebanon, NH (US); Sonia Das, Cambridge, MA (US); and Alison M. O'Neill, Cambridge, MA (US)
Assigned to Surface Oncology, Inc., Cambridge, MA (US)
Filed by Surface Oncology, Inc., Cambridge, MA (US)
Filed on Sep. 15, 2020, as Appl. No. 17/21,223.
Claims priority of provisional application 63/075,567, filed on Sep. 8, 2020.
Claims priority of provisional application 63/003,191, filed on Mar. 31, 2020.
Claims priority of provisional application 62/975,519, filed on Feb. 12, 2020.
Claims priority of provisional application 62/935,969, filed on Nov. 15, 2019.
Claims priority of provisional application 62/932,249, filed on Nov. 7, 2019.
Claims priority of provisional application 62/902,285, filed on Sep. 18, 2019.
Claims priority of provisional application 62/901,153, filed on Sep. 16, 2019.
Prior Publication US 2021/0095041 A1, Apr. 1, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01); A61K 39/395 (2006.01); A61K 31/337 (2006.01); A61K 31/7068 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2896 (2013.01) [A61K 31/337 (2013.01); A61K 31/7068 (2013.01); A61K 39/39541 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/51 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 19 Claims
 
1. An isolated antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein:
a. the VH comprises the amino acid sequence of SEQ ID NO: 12 and the VL comprises the amino acid sequence of SEQ ID NO: 18; or
b. the VH comprises the amino acid sequence of SEQ ID NO: 112 and the VL comprises the amino acid sequence of SEQ ID NO: 118; or
c. the VH comprises the amino acid sequence of SEQ ID NO: 212 and the VL comprises the amino acid sequence of SEQ ID NO: 218; or
d. the VH comprises the amino acid sequence of SEQ ID NO: 312 and the VL comprises the amino acid sequence of SEQ ID NO: 318; or
e. the VH comprises the amino acid sequence of SEQ ID NO: 412 and the VL comprises the amino acid sequence of SEQ ID NO: 418; or
f. the VH comprises the amino acid sequence of SEQ ID NO: 512 and the VL comprises the amino acid sequence of SEQ ID NO: 518; or
g. the VH comprises the amino acid sequence of SEQ ID NO: 612 and the VL comprises the amino acid sequence of SEQ ID NO: 618; or
h. the VH comprises the amino acid sequence of SEQ ID NO: 712 and the VL comprises the amino acid sequence of SEQ ID NO: 718; or
i. the VH comprises the amino acid sequence of SEQ ID NO: 812 and the VL comprises the amino acid sequence of SEQ ID NO: 818; or
j. the VH comprises the amino acid sequence of SEQ ID NO: 912 and the VL comprises the amino acid sequence of SEQ ID NO: 918; or
k. the VH comprises the amino acid sequence of SEQ ID NO: 1012 and the VL comprises the amino acid sequence of SEQ ID NO: 1018; or
l. the VH comprises the amino acid sequence of SEQ ID NO: 2012 and the VL comprises the amino acid sequence of SEQ ID NO: 2018; or
m. the VH comprises the amino acid sequence of SEQ ID NO: 3012 and the VL comprises the amino acid sequence of SEQ ID NO: 3018; or
n. the VH comprises the amino acid sequence of SEQ ID NO: 4012 and the VL comprises the amino acid sequence of SEQ ID NO: 4018; or
o. the VH comprises the amino acid sequence of SEQ ID NO: 5012 and the VL comprises the amino acid sequence of SEQ ID NO: 5018; or
p. the VH comprises the amino acid sequence of SEQ ID NO: 6012 and the VL comprises the amino acid sequence of SEQ ID NO: 6018; or
q. the VH comprises the amino acid sequence of SEQ ID NO: 7012 and the VL comprises the amino acid sequence of SEQ ID NO: 7018; or
r. the VH comprises the amino acid sequence of SEQ ID NO: 8012 and the VL comprises the amino acid sequence of SEQ ID NO: 8018; or
s. the VH comprises the amino acid sequence of SEQ ID NO: 9012 and the VL comprises the amino acid sequence of SEQ ID NO: 9018; or
t. the VH comprises the amino acid sequence of SEQ ID NO: 10012 and the VL comprises the amino acid sequence of SEQ ID NO: 10018; or
v. the VH comprises the amino acid sequence of SEQ ID NO: 30012 and the VL comprises the amino acid sequence of SEQ ID NO: 30018.